BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare ...

DUBLIN, Ireland, and Boston MA, October 18, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for ...

Acromegaly is one of those diseases that immediately caught our attention when we first heard about it in medical school. We stared at the textbook pictures of big hands and coarse faces—maybe a very ...

This prospective, cross-sectional, and comparative study included 30 patients with acromegaly (study group) and 30 healthy subjects (control group). The subfoveal choroidal thickness (SFCT), foveal ...

WASHINGTON (AP) _ Sufferers of a rare disease that causes out-of-control growth are about to get a novel treatment that targets one of the condition's key villains. The Food and Drug Administration ...

Higher on-treatment serum insulin-like growth factor I levels may be associated with higher all-cause mortality risk among adults with acromegaly receiving the growth hormone blocker pegvisomant, ...